Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2015 Dec 7;5:18117. doi: 10.1038/srep18117

Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury

Luping Huang 1,a,*, Lin Zhang 2,1,*, Huiming Ju 1,3, Qingtian Li 1, Jenny Szu-Chin Pan 1, Zahraa Al-Lawati 1, David Sheikh-Hamad 1,b,*
PMCID: PMC4671147  PMID: 26640170

Abstract

Thrombin-induced and proteinase-activated receptor 1 (PAR1)-mediated signaling increases ROS production, activates ERK, and promotes inflammation and fibroblast proliferation in bleomycin-induced lung injury. Stanniocalcin-1 (STC1) activates anti-oxidant pathways, inhibits inflammation and provides cytoprotection; hence, we hypothesized that STC1 will inhibit thrombin/PAR1 signaling and protect from bleomycin-induced pneumonitis. We determined thrombin level and activity, thrombin-induced PAR-1-mediated signaling, superoxide generation and lung pathology after intra-tracheal administration of bleomycin to WT and STC1 Tg mice. Lungs of bleomycin-treated WT mice display: severe pneumonitis; increased generation of superoxide; vascular leak; increased thrombin protein abundance and activity; activation of ERK; greater cytokine/chemokine release and infiltration with T-cells and macrophages. Lungs of STC1 Tg mice displayed none of the above changes. Mechanistic analysis in cultured pulmonary epithelial cells (A549) suggests that STC1 inhibits thrombin-induced and PAR1-mediated ERK activation through suppression of superoxide. In conclusion, STC1 blunts bleomycin-induced rise in thrombin protein and activity, diminishes thrombin-induced signaling through PAR1 to ERK, and inhibits bleomycin-induced pneumonitis. Moreover, our study identifies a new set of cytokines/chemokines, which play a role in the pathogenesis of bleomycin-induced lung injury. These findings broaden the array of potential therapeutic targets for the treatment of lung diseases characterized by thrombin activation, oxidant stress and inflammation.

Thoracic malignancies are among the leading cause of morbidity and mortality. Radiation and chemotherapy, commonly used for the treatment of thoracic malignancies, are frequently associated with pneumonitis and pulmonary fibrosis1. The pathogenesis of pulmonary fibrosis involves alveolar epithelial and endothelial cell injury, increased reactive oxygen species (ROS) and expression of cytokines/chemokines, inflammation, fibroblast activation and proliferation with consequent matrix deposition in the alveolar and interstitial spaces, leading to tissue damage, fibrosis, reduced lung volume and compliance2.

Thrombin is a multifunctional serine protease that catalyzes the conversion of fibrinogen to fibrin and plays an important role in blood coagulation. In addition, thrombin is involved in tissue repair, wound healing and lung fibrosis via activation of protease-activated receptors (PARs), a family of G protein–coupled receptors comprised of four members (PAR1–4)3,4. PAR1 has been identified as the major receptor for thrombin-induced mitogenic, inflammatory, and fibrotic effects3,4. There is considerable evidence to suggest important roles for thrombin, ROS and extracellular regulated kinase (ERK) activation in the pathogenesis of inflammation and immune-mediated lung injury5.

Mammalian STC1 is ubiquitously expressed and has been detected in many tissues including the lungs6. While it circulates in the blood, it is believed to function as an autocrine/intracrine substance7. Studies from our lab suggest that mammalian STC1 upregulates uncoupling proteins and suppresses mitochondrial superoxide generation8; and in doing so, it inhibits macrophage function8, attenuates cytokine-induced rise in endothelial permeability9 and migration of lymphocytes and macrophages across endothelial cells10. Combined, these effects predict potent anti-inflammatory action. Indeed, STC1 Tg mice are protected from ischemia/reperfusion kidney injury11 and anti-glomerular basement membrane (GBM) glomerulonephritis (GN)12; models of kidney injury involving ROS and inflammation. Of note, protection from anti-GBM glomerulonephritis in STC1 Tg mice, is associated with diminished expression of macrophage chemotaxis protein-1 (MCP-1), transforming growth factor-β (TGF-β) and MIP2 in the kidney12. Based on our observations, we hypothesized that transgenic overexpression of STC1 in mice will inhibit thrombin actions, diminish ROS production and inflammation, and protect from bleomycin-induced lung injury and inflammation.

Our data reveal novel effects by STC1: transgenic overexpression of STC1 diminishes thrombin protein abundance and activity; decreases superoxide generation; down-regulates ERK activity; decrease cytokines/chemokines release; and reduces vascular permeability and accumulation of inflammatory cells in the lungs after bleomycin administration. Mechanistic in vitro data suggest that STC1 inhibits thrombin/PAR1-mediated signaling to ERK through suppression of superoxide. Our findings are clinically relevant and may provide new therapeutic targets for the treatment/prevention of radiation and chemotherapy induced-pneumonitis, and consequent pulmonary fibrosis.

Materials and Methods

Materials

All materials were purchased from Sigma Aldrich Inc. (St Louis, MO) unless stated otherwise. Recombinant human STC1 (rSTC1) was purchased from MyBioSource (San Diego, CA). MnTBAP, rat anti-F4/80 (macrophage marker), rabbit anti-CD3 (T-cell marker), mouse anti-actin and mouse anti-GAPDH were purchased from EMD Millipore (Billerica, MA). SCH79797 was purchased from Fisher Scientific (Houston, TX). Goat anti-hSTC1 antibodies and Goat anti-thrombin antibodies were purchased from Santa Cruz (Santa Cruz, CA). Rabbit anti-ERK and rabbit anti-p-ERK were purchased from Cell Signaling (Danvers, MA).

Mice

STC1 Tg mice on C57B/6 genetic background were generated by Varghese et al.13 and were further characterized and described elsewhere11,12. All studies were carried out using mice homozygous for the transgene (derived from line 213), and WT generated from crosses between heterozygous mice. Transgenic mice display elevated rSTC1 in the serum and preferential expression of the transgene in the heart, liver, brain, testis, mammary glands and adipose tissue13. Mice were maintained in air conditioned rooms under pathogen-free conditions with 12 h/12 h light/dark cycles, and were given free access to food and water. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health, and the experiments were approved by Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC).

Mouse model of bleomycin-induced lung injury

Age-matched WT and STC1 Tg mice were used. Mice were anesthetized and treated with single-dose of saline or bleomycin (2 U/kg; in a total volume of 50 μl of saline) via intra-tracheal injection as previously described14; 6–10 mice were used for each group at each time point.

Immunohistochemistry and morphology

Whole lungs were removed, fixed by Methanol-Carnoy (Methacarn), paraffin-embedded, and 5-μm sections were obtained. Lung tissue was stained with: H&E (morphology); anti-F4/80 (macrophages); anti-CD3 (lymphocytes). Detection was carried out using peroxidase enzyme-based detection system (Vector Laboratories), and photomicrographs were taken using Nikon Eclipse 80i microscope system. Neutrophils were identified based on morphology and counted. The severity of lung injury was determined as published by Li et al.15, and grading was based on the degree of inflammation and extent of lung injury: grade 0, normal tissue; grade 1, <20% of the surveyed tissue is injured and mild inflammation; grade 2, 20–50% of the surveyed tissue is injured and moderate inflammation; and grade 3, >50% of the surveyed tissue is injured with severe inflammation. The mean score from all examined fields was calculated as the injury/inflammation score (IS).

Measurement of pulmonary vascular permeability

Vascular permeability was measured using a modification of a previously described method16. Briefly, Evans blue dye (20 mg/kg body weight) prepared in PBS was injected through the tail vein. Mice were sacrificed after 1 hour, the lung vasculature was perfused with PBS; the lungs were excised, placed in 2 mL of formamide, and homogenized. The homogenates were incubated at 60 °C for 16 hours, followed by centrifugation at 8000 g for 10 min, and the supernatants were collected. Absorbance of the supernatants was measured at 620 nm and normalized to the absorbance of wells containing assay buffer alone, giving permeability index (expressed as OD/mg protein).

Thrombin activity assay

Lung tissue was rinsed in PBS, and homogenized in 500 μL of PBS, followed by centrifugation at 3000 g for 5 min, at 4 °C; the supernatant was collected and the protein was quantitated (Bradford’s method). Tissue lysates (100 μg protein/100 μL) were placed in black wall 96-well flat-bottom plates, and assayed using SensoLyte® 520 thrombin activity assay kit (AnaSpec, Inc.; Fremont, CA) as per manufacturer’s instructions. This kit contains a novel internally quenched 5-FAM/QXL® 520 fluorescence resonance energy transfer (FRET) substrate for thrombin. Cleavage of the FRET substrate by thrombin separates the fragments, releasing 5-FAM fluorescence (monitored at excitation/emission = 490 nm/520 nm).

Superoxide measurements

Superoxide was measured using a modification of a previously described method11. Briefly, lung tissue was homogenized in 500 μL sucrose buffer (composition: 0.31 M sucrose; 10 mM Tris-HCl; pH 7.4) on ice, followed by protein quantitation (Bradford’s method). Tissue lysates (100 μg protein/100 μL) were placed in clear flat-bottom wells (96-well plate), containing excess dihydroethidium (DHE; 100 μM), in a final volume of 100 μL/well. Absorbance values (excitation/emission at 530/620 nm) were normalized to the absorbance of wells containing equimolar concentrations of DHE alone, and expressed as OD/μg protein.

Cell culture

Human basal alveolar epithelial cells (A549 cells) were cultured in Dulbecco’s Modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and 100 U/mL of each penicillin and streptomycin, and maintained in an incubator set at 37 °C and containing humidified atmosphere of 5% CO2 in air. At 80% cell confluence, the growth medium was replaced with DMEM containing 1% FBS and the cells were weaned overnight. The following day, the medium was replaced with 1 mL of DMEM devoid of FBS or growth factors, and cells were treated with one of the following: thrombin (1 U/mL); rSTC1 (200 ng/mL); SCH79797 (a PAR1 antagonist; 4 μM); MnTBAP (antioxidant; 0.1 mM); paraquat (a superoxide generator; 40 μM); or combination of the above. Cells were collected, assayed for MitoSOX (Invitrogen, Carlsbad, CA) fluorescence, or lysed in radioimmunoprecipitation assay buffer [RIPA; composition: 150 mM NaCl; 50 mM Tris-HCl (pH 7.4); 1% NP-40; 0.25% sodium deoxycholate; 1 mM ethylene diamine tetra acetic acid (EDTA)] containing complete mini protease inhibitor (Roche Applied Science, Indianapolis, IN), and phosphatase inhibitor cocktail (Sigma) for Western blot analysis. MitoSOX permeates live cells and selectively targets the mitochondria; it is rapidly oxidized by superoxide and emits red fluorescence.

MitoSOX fluorescence assay

Measurement of superoxide in cells was performed as previously described11. Briefly, cells were seeded onto coverslips placed at the bottom of 6-well plates and treated as detailed above. MitoSOX™ and bis Benzimide 33342 trihydrochloride (Hoechst; Sigma; used for counter stain) were added to the culture media for 10 min, at a final concentrations of 5 μM and 0.2 μg/mL, respectively. Following incubation with MitoSOX and Hoechst, cells were rinsed in PBS and fluorescence was visualized (excitation/emission at 510/580 nm).

Western blotting

Lysates, prepared from A549 cells or whole lung tissue as previously described11, were suspended in RIPA buffer containing 1x cocktail of proteinase and phosphatase inhibitors, and centrifuged at 8000 g, 4 °C for 10 min, to remove cell debris. Twenty μg of protein were resolved on 12% SDS-PAGE, transferred to nitrocellulose membrane and incubated with primary antibodies for: STC1; ERK; p-ERK; thrombin (also recognizes prothrombin); actin or GAPDH. After wash with PBS containing 0.1% Tween-20, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody. The bound antibodies were visualized using chemiluminescence. Densitometric analysis of target proteins was performed using NIH ImageJ Software. The activity of ERK was determined based on the ratio of p-ERK/t-ERK bands.

Cytokine polymerase chain reaction (PCR) array

Mouse Common Cytokines RT2 Profiler™ PCR Array (QIAGEN; Frederick, MD), employing a set of optimized PCR primers was used to profile the expression of 84 important cytokine genes using real-time (RT)-PCR CFX 96 system (Bio-Rad; Hercules, CA). This array includes tumor necrosis factor-α (TNF-α), interferons, interleukins, bone morphogenic proteins (BMP) and members of the TGF-β family. Also represented are various growth factors (colony-stimulating, fibroblast, insulin-like, platelet-derived, transforming, and vascular endothelial). Total RNA was isolated from whole lungs, using TRIzol (Invitrogen; Grand Island, NY). RNAs were treated with DNase I prior to cDNA synthesis, and 150 ng of total RNA were reverse-transcribed into cDNA using the RT2 First Stand Kit (QIAGEN, Frederick, MD) as per manufacturer’s instructions. Relative mRNA expression levels were calculated using RT2 Profiler Array Data Analysis software v3.5 (QIAGEN). Gene expression levels were normalized to five housekeeping genes included in the Array. Fold changes in gene expression were calculated by the software using the 2-∆∆Ct method. 2-fold or greater change in gene expression was set as the threshold for a meaningful change in gene expression. Data represent the mean± SEM of three independent determinations.

ELISA

We used an enzyme-linked immunosorbent assay (ELISA) to determine the levels of Spp1 and CXCL16 proteins in lung tissue. Briefly, MaxiSorp (Nunc) plate wells were coated with anti-Spp1 or anti-CXCL16 antibodies (50 μL/well) at 37 °C for 2–3 hours, followed by wash in PBS (6 times); the wells were then blocked with 1% BSA in PBS for 1 hour, washed again in PBS (6 times) before the addition of equal amounts of protein lysates, followed by gentle agitation at RT for 2 h; lysis buffer was used as negative control. Next, biotinylated anti-CXCL16 or anti-Spp1 (50 μl/well) was added and incubated for 1 hour; wells were then washed in PBS (6 times), followed by the addition of poly-HRP streptavidin (50 μl/well) and incubation in the dark for 30 additional minutes. Following wash in PBS (6 times), freshly prepared TMB-peroxidase solution (100 uL/well) was added for 2–5 min, and the reaction was stopped using 1 N H2SO4. Signal intensity was determined using ELISA reader at A450 nm.

Statistics

Statistical analysis was performed using Graph Pad Prism Software version 4. Differences between data groups were evaluated for significance using unpaired t-test, one way ANOVA or Newman-Keuls for multiple comparisons. Statistical significance was defined by a p < 0.05.

Results

STC1 protects from acute bleomycin-induced pneumonitis

We applied a well-established bleomycin-induced lung injury model to WT and STC1 Tg mice. Compared with WT mice, STC1 Tg mice display elevated serum levels of STC1 protein; but equal levels of STC1 in lung tissues (Fig. 1). Figure 2A,B show normal lung morphology in saline-treated (sham) WT and STC1 Tg mice, respectively. One week after treatment with bleomycin (BLM), WT lungs showed interstitial edema, severe distortion of lung morphology (Fig. 2C and Table 1), and marked infiltration with lymphocytes (Figs 2G and 3), macrophages (Figs 2K and 3) and neutrophils (Fig. 3). On the other hand, lungs of bleomycin-treated STC1 Tg mice displayed normal morphology (Fig. 2D and Table 1) that was indistinguishable from the morphology of saline-treated WT or STC1 Tg mice (Table 1), and revealed fewer lymphocytes (Figs 2H and 3), macrophages (Figs 2L and 3) and neutrophils (Fig. 3). The data suggest that transgenic overexpression of STC1 protects from acute bleomycin-induced lung injury and pneumonitis.

Figure 1. Lung tissue and serum levels of STC1 in WT and STC1 Tg mice.

Figure 1

Open in a new tab

(A) Equal amounts of serum proteins from WT and STC1 Tg mice were run on SDS-PAGE, and Western blot was reacted with anti-STC1 antibodies. (B) Lung tissue lysates were reacted with anti-STC1 or anti-actin; representative blots are shown. (C) STC1 band intensities were normalized to actin bands, and bar graph depicts the mean± SEM (n = 5).

Figure 2. Transgenic overexpression of STC1 inhibits bleomycin-induced pneumonitis.

Figure 2

Open in a new tab

Wild type (WT) or STC1 transgenic (Tg) mice were treated with either saline or bleomycin (BLM). Lung tissue was harvested after one week, and subjected to immunohistochemistry. Top panels, H&E staining for morphology. Middle panels, show staining with anti-CD3 (lymphocytes). Bottom panels show staining with anti-F4/80 (macrophages).

Table 1. Morphometric analysis of lung injury.

  WT Sham STC1 Tg Sham WT BLM STC1 Tg BLM
IS 0 0 2 + 0.58 0.5 ± 0.29
P-value NS NS *P < 0.01 #P < 0.05
Open in a new tab

H&E stained sections were viewed at ×200 magnification, and tissue injury grading was carried out as described in methods. The mean score from all examined fields was calculated as the inflammation score (IS). Means and ± SEMs are provided (n = 3–4). *P < 0.01, WT BLM vs WT Sham; #P < 0.05, WT BLM vs STC1 Tg BLM; NS, WT Sham vs STC1 Tg Sham, or STC1 Tg Sham vs STC1 Tg BLM.

Figure 3. Transgenic overexpression of STC1 diminishes lung infiltration with macrophages, T-cells and neutrophils after bleomycin treatment.

Figure 3

Open in a new tab

Wild type (WT) or STC1 transgenic (Tg) mice were treated with saline or bleomycin (BLM). Lung tissue was harvested after one week and stained with H&E for neutrophil count, anti-CD3 (lymphocytes), or anti-F4/80 (macrophages). Bar graphs show count of macrophages, T-cells and neutrophils (identified based on morphology), and represent the mean ± SEM (n = 6).

Transgenic overexpression of STC1 maintains vascular barrier function and inhibits bleomycin-induced lung inflammation

In the current experiment, we examined vascular permeability across the pulmonary vasculature (measured as tissue retention of Evans blue) one week after treatment of WT and STC1 Tg mice with bleomycin. While vascular permeability increased in bleomycin-treated WT mice, we observed no changes in pulmonary vascular permeability of bleomycin-treated STC1 Tg mice (Fig. 4). These finding are consistent with preservation of endothelial barrier function by STC1, an effect that may contribute to the paucity of inflammatory cells we observe in the lungs of STC1 Tg mice after bleomycin treatment.

Figure 4. Transgenic overexpression of STC1 preserves vascular barrier function in the lung following bleomycin treatment.

Figure 4

Open in a new tab

Evans blue dye was injected through the tail vein of WT and STC1 Tg mice one week after saline or BLM treatment. Lung tissue was harvested, homogenized; and the absorbance of Evans blue dye was measured at 620 nm. Values represent means ± SEM (n = 5).

Transgenic overexpression of STC1 diminishes thrombin level

Tissue injury elicits immediate responses that activate the coagulation cascade and lead to thrombin generation17, which has been shown to play an important role in lung inflammation and tissue repair18. Thrombin levels are markedly elevated in humans and experimental models of lung fibrosis19,20; hence, we examined thrombin level and activity in the lungs of WT and STC1 Tg mice after treatment with bleomycin. Compared with saline, treatment with bleomycin increased thrombin protein level and activity in the lungs of WT mice; and the increase in thrombin activity matches the increase in thrombin protein abundance (Fig. 5). However, treatment of STC1 Tg mice with bleomycin did not increase thrombin protein level or activity in the lungs beyond the baseline levels observed in saline-treated STC1 Tg mice. These data suggest that inhibition of thrombin in STC1 Tg mice may underlie (at least in part) the protection from bleomycin-induced lung injury.

Figure 5. Transgenic overexpression of STC1 diminishes thrombin protein and activity in the lung after bleomycin treatment.

Figure 5

Open in a new tab

One week after intra-tracheal administration of bleomycin, lungs were harvested, homogenized, and assayed for thrombin protein abundance and activity as described in methods. (A) The proteolytic activity of thrombin is expressed in relative fluorescent units. Values represent means ± SEM (n = 5). (B,C) Transgenic overexpression of STC1 diminishes thrombin protein expression. WT or STC1 Tg mice were treated with either saline or BLM. One week later, lungs were harvested, homogenized, protein lysates were resolved on SDS-PAGE, and Western blots reacted with anti-thrombin or anti-GAPDH. (B) Representative blots are shown. (C) Bar graph depicts band intensities for thrombin normalized to GAPDH; data represent the mean± SEM (n = 6–10).

Suppression of superoxide by STC1 may contribute to the protection from bleomycin-induced lung injury

Published data from our lab show STC1 suppresses superoxide generation in macrophages8 and cardiomyocytes21 via UCPs-dependent pathway. ROS play an important role in the pathogenesis of inflammation following bleomycin-induced lung injury22, and in the current experiment we sought to determine superoxide levels in the lungs of bleomycin treated mice. Our data reveal increased superoxide levels in WT lungs 1 week after treatment with bleomycin (Fig. 6), but not at 4 weeks (data not shown). On the other hand, superoxide generation was unchanged in STC1 Tg lungs after bleomycin treatment, and was indistinguishable from superoxide levels we observe in the lungs of saline-treated WT or STC1 Tg mice. Suppression of superoxide generation in STC1 Tg lungs after bleomycin treatment is likely related to decreased inflammation as shown above, as well as direct effects by STC1 on lung tissue; these results are in agreement with previously reported actions of STC1 to suppress superoxide generation in other tissues8,21 and may provide another mechanism for inhibition of bleomycin-induced lung injury.

Figure 6. Transgenic overexpression of STC1 inhibits ROS production in the lungs after bleomycin treatment.

Figure 6

Open in a new tab

One week after intra-tracheal administration of saline or BLM, lungs were harvested, homogenized, incubated with DHE, and fluorescence intensity was measured at excitation 530 nm, emission 620 nm. Values represent means ± SEM (n = 5).

STC1 inhibits bleomycin-induced ERK1/2 activation in vivo

PAR1-mediated activation of PKC and ERK1/2 plays a critical role in thrombin-induced mitogenic, inflammatory, and pro-fibrotic effects4,23,24,25. ERK1/2 activation by thrombin follows PKC activation25, and in the current experiments, we sought to determine ERK1/2 activity (pERK1/2/tERK1/2) in WT and STC1 Tg lungs 1 week after saline (sham) or bleomycin (BLM) treatment. ERK1/2 activity was significantly increased in the lungs of WT mice after bleomycin treatment. ERK1/2 activity in the lungs of saline-treated STC1 Tg mice was numerically lower compared with saline-treated WT mice and was unchanged after blemoycin treatment (Fig. 7). Thus, STC1 inhibits baseline ERK1/2 activity, and blunts activation of ERK1/2 upon treatment with bleomycin.

Figure 7. Transgenic overexpression of STC1 inhibits belomycin-induced ERK1/2 phosphorylation.

Figure 7

Open in a new tab

WT or STC1 Tg mice were treated with either saline or BLM. One week later, lungs were harvested, homogenized, protein lysates were resolved on SDS-PAGE, and Western blots reacted with anti-ERK1/2 or anti-pERK1/2. Bar graph shows band intensities for pERK1/2 normalized to tERK1/2; data represent the mean± SEM (n = 6–10).

Blunted expression of pro-inflammatory cytokines/chemokines in STC1 Tg lungs after belomycin treatment

Thrombin-induced activation of ERK1/2 stimulates the expression of pro-inflammatory cytokines/chemokines and pro-fibrotic growth factors including: TNF-α; interleukin-6 (IL-6); IL-8; IL-13; IL-21; IL-1β; MCP-1; MIP-1; TGF-β; PDGF and bFGF26,27. Mouse Common Cytokines RT2 Profiler™ PCR Array was used to profile the expression of 84 important cytokine/chemokines and growth factors genes (see methods) in WT and STC1 Tg lungs after bleomycin treatment. As shown in Table 2, and compared with lungs of saline-treated WT mice, lungs of bleomycin-treated WT mice displayed significantly higher expression of: C-C chemokine ligand 17 (Ccl17; 6.7-fold); C-C chemokine ligand 2 (Ccl2; 6.7-fold); C-C chemokine ligand 7 (Ccl7; 8-fold); C-X-C chemokine 10 (Cxcl10; 4.6-fold); C-X-C chemokine 16 (Cxcl16; 5.1-fold); IL18 (3-fold); interleukin 1 receptor antagonist (IL1rn; 3.5-fold); leukemia inhibitory factor (Lif; 3.1-fold); secreted phosphoprotein 1 (Spp1; 19-fold) and beta-glucuronidase (Gusb; 2.3-fold); while IL5 was under-expressed (-2.7-fold). Cytokine/chemokine profile in the lungs of bleomycin-treated STC1 Tg mice was not different from the profile observed in saline-treated STC1 Tg mice (data not shown). Comparing the profile of cytokines/chemokines in the lungs of bleomycin-treated STC1 Tg mice with that of bleomycin-treated WT mice, we observe significantly lower expression of Ccl17 (-2-fold), chemokine (C-C motif) ligand 19 (Ccl19; -2-fold), Ccl2 (-3-fold), Ccl7 (-4-fold), Cxcl10 (-2.3-fold), Cxcl16 (-2.9-fold) and Spp1 (-6-fold) (Table 3); these constitute 7 out of 10 bleomycin-induced cytokines/chemokines in WT mice (Table 2). To validate the cytokine PCR array data, we determined protein levels of CXCL16 and Spp1 in lung tissue, using ELISA, and found increased expression of these proteins in the lungs of bleomycin-treated WT mice, but not in the lungs of bleomycin-treated STC1 Tg mice (Fig. 8). Our data identify new and previously unrecognized cytokines/chemokines that appear to play a role in the pathogenesis of bleomycin-induced acute lung injury; transgenic overexpression of STC1 blunts the expression of these cytokines/chemokines.

Table 2. Cytokine/chemokines that display increased expression in lungs of WT after bleomycin treatment, compared with lungs of saline-treated WT (red font in the “fold increase” column denotes fold upregulation relative to WT sham; n = 3).

Genes Over-Expressed in WT BLM vs. WT sham
Gene Symbol Fold increase p-value
Ccl17 6.6295 0.003206
Ccl2 6.7706 0.016282
Ccl3 2.9236 0.081883
Ccl7 8.0755 0.002946
Cxcl10 4.6159 0.004979
Cxcl13 3.4948 0.215463
Cxcl16 5.1325 0.003251
Il18 3.0327 0.030913
Il1rn 3.4529 0.00796
Lif 3.0833 0.006896
Spp1 18.9586 0.005687
Gusb 2.2509 0.005652
Open in a new tab

Table 3. Comparison of cytokine/chemokine profile in the lungs of bleomycin-treated WT mice with bleomycin-treated STC1 Tg mice (red font in the “fold increase” column denotes fold upregulation relative to STC1 Tg BLM; n = 3).

Genes Over-Expressed in WT BLM vs. STC1Tg BLM
Gene Symbol Fold increase p-value
Ccl17 2.0218 0.023863
Ccl19 2.0099 0.004189
Ccl2 2.99 0.033351
Ccl3 2.2521 0.219016
Ccl7 4.0391 0.005296
Cxcl10 2.2518 0.015744
Cxcl13 2.2942 0.309659
Cxcl16 2.8609 0.028026
Spp1 6.1254 0.011208
Tnfsf10 3.1896 0.064755
Open in a new tab

Figure 8. Transgenic overexpression of STC1 inhibits bleomycin-induced expression of CXCL16 and Spp1.

Figure 8

Open in a new tab

WT or STC1 Tg mice were treated with either saline or BLM for one week. Lungs were harvested, homogenized, protein lysates were assayed for CXCL16 and Spp1 using ELISA. Bar graphs depict the means+ SEM (n = 3).

STC1 inhibits bleomycin-induced thrombin/PAR1/ERK1/2 signaling in vitro through suppression of superoxide

Our in vivo data suggest that transgenic overexpression of STC1 diminishes thrombin protein and activity, superoxide generation, ERK1/2 activation and release of cytokines/chemokines in the lungs after bleomycin treatment. To further characterize mechanisms of STC1 action, we utilized A549 pulmonary epithelial cells, which express high level of PAR128 (the mediator of thrombin signaling), for in vitro analysis of the effects of thrombin and rSTC1. Thrombin activated ERK1/2 through PAR1, as the effect of thrombin was abolished by PAR1 specific inhibitor SCH79797 (Figs 9A and 7B)29. Similarly, STC1 inhibited thrombin-induced ERK1/2 activation (Fig. 9A). These data suggest inhibition of thrombin/PAR1 signaling by STC1 at the cellular level. We next examined the effect of STC1 on thrombin-induced superoxide generation. As shown in Fig. 9C,D, thrombin treatment increased mitochondrial superoxide generation markedly, an effect that was diminished by either SCH79797 or rSTC1, consistent with STC1-mediated inhibition of thrombin/PAR1-induced superoxide generation.

Figure 9. Recombinant STC1 (rSTC1) inhibits thrombin-induced and PAR1-mediated ERK1/2 activation and superoxide production.

Figure 9

Open in a new tab

A549 cells were pre-treated with SCH79797 (4 μM) for 30 min or STC1 (200 ng/ml) for 2 h, followed by thrombin treatment (1 U/ml) for 10 min at 37 °C. Cells were harvested, lysed and proteins were resolved on SDS-PAGE. Western blots were reacted with anti-ERK1/2 or anti-pERK1/2. (A) Representative blots are shown. (B) Quantitation of pERK1/2 band intensities normalized to total ERK1/2 bands; bar graph depicts the mean ± SEM (n = 3). Thrombin induces superoxide through PAR1; recombinant STC1 attenuates thrombin-induced superoxide generation. A549 cells were treated as above, incubated with MitoSOX (5 μM) and Hoechst (0.2 μg/ml), and MitoSOX fluorescence was visualized (excitation 510 nm, emission 580 nm). (C) Representative images are shown; magnification: 200X. (D) Quantitation of MitoSOX fluorescence in A549 cells treated as above; bar graph depicts the mean± SEM (n = 3).

ERK1/2 activity is redox-sensitive30, and since STC1 suppresses superoxide generation, we examined the hypothesis that STC1 inhibits thrombin-induced ERK1/2 activation through suppression of superoxide. Indeed, while either thrombin or paraquat (a superoxide generator) induced ERK1/2 activation, MnTBAP [a cell permeable superoxide dismutase (SOD) mimic] or STC1 inhibited thrombin-induced ERK1/2 activation (Fig. 10). However, STC1 failed to block thrombin-induced ERK1/2 activation in the presence of paraquat (a superoxide generator). These data suggest that STC1 inhibits thrombin-induced ERK1/2 activation through suppression of superoxide generation.

Figure 10. Recombinant STC1 inhibits thrombin-mediated ERK1/2 activation through suppression of superoxide production.

Figure 10

Open in a new tab

A549 cells were pre-treated with the following agents, either singly, or in combination, followed by thrombin treatment (1 U/mL) for 10 min at 37 °C: paraquat (40 μM) for 4 h; MnTBAP (0.1 mM) for 30 min; STC1 (200 ng/mL) for 2 h. Cells were harvested, lysed, and proteins were resolved on SDS-PAGE; Western blots were reacted with anti-ERK1/2 or anti-pERK1/2. (A) Representative blots are shown. (B) Quantitation of pERK1/2 band intensities normalized to total ERK1/2 bands; bar graph depicts the mean + SEM (n = 3). (C) A549 cells, treated as above were incubated with MitoSOX (5 μM) and Hoechst (0.2 μg/ml) for 10 min, and MitoSOX fluorescence was visualized (excitation 510 nm, emission 580 nm). Representative images are shown; magnification: 200X. (D) Quantitation of MitoSOX fluorescence in A549 cells treated as above; bar graph depicts the mean± SEM (n = 3).

Discussion

Cumulative evidence suggests that thrombin promotes inflammation and fibroblast proliferation following bleomycin- and radiation-induced lung injuries19,20. PAR1 is expressed on epithelial cells, monocytes/macrophages and vascular endothelial cells. It is a key mediator of thrombin’s effects, and stimulation of PAR1 increases endothelial permeability, mitogenic responses, inflammation and fibrosis4,23,31,32. Previous work suggested that mesenchymal stem cells decrease oxidative stress, ER-stress response and TGF-β1 synthesis in alveolar epithelial cells exposed to bleomycin, through release of STC133. However, the mechanism of STC1 actions remained to be defined. In the current work, we elucidated mechanisms of STC1-mediated protection from bleomycin-induced lung injury, and identified novel and hitherto unrecognized actions by STC1; i.e., inhibition of thrombin protein and activity; findings that are crucial for the design of future therapies for lung injury induced by radiation- or bleomycin.

Our study reveals increased thrombin protein abundance and activity in the lungs of WT mice after administration of bleomycin; however, thrombin abundance and activity were unchanged in the lungs of bleomycin-treated STC1 Tg mice. Since thrombin-induced and PAR1-mediated signaling increases the production of reactive oxygen species and ERK activation and inflammation in bleomycin-induced lung injury, we expected these to be mitigated by STC1. Indeed, compared with lungs of WT mice, lungs of STC1 Tg mice display lesser superoxide generation, ERK activation, production of cytokines/chemokines, and infiltration with lymphocytes, macrophages and neutrophils after bleomycin treatment.

What happens beyond PAR1 activation by thrombin? Current in vitro data in cultured pulmonary epithelial cells suggest that thrombin increases superoxide generation and activates ERK through PAR1-mediated pathway; STC1 attenuates baseline ERK activity, and blunts further activation of ERK by thrombin. Mechanistically, the actions of STC1 correlate with its effects on the redox state. Similar to paraquat (a superoxide generator), treatment of pulmonary epithelial cells with thrombin increases superoxide and ERK activity. And similar to MnTBAP (a cell permeable SOD mimic), treatment with STC1 diminishes superoxide level and inhibits thrombin-induced ERK1/2 activation. Importantly, STC1 fails to block thrombin-induced ERK1/2 activation in the presence of the superoxide generator paraquat. ERK phosphorylation and activation are redox sensitive34,35, and thrombin appears to increase ERK activity through increasing superoxide generation. Because STC1 suppresses superoxide generation, it provides a mechanism for inhibition of thrombin-mediated ERK1/2 activation downstream of PAR1. Thus, STC1 inhibits thrombin/PAR1-mediated ERK activation (signaling) through suppression of superoxide generation.

The regulation of thrombin activity by STC1 deserves further comment. A previous report suggested that activation of thrombin-activatable fibrinolysis inhibitor [(TAFI); an inhibitor of osteopontin (Spp1) and complement system components C3a & C5a] protects from acute lung injury36. Thus, inhibition of thrombin protein and activity as a mechanism for lung protection by STC1 is consistent with previous observations, and given the role of STC1 in diminishing thrombin-induced superoxide generation and ERK1/2 activation, our study hints at a potential innovative approach for the management of thrombotic conditions.

Survey of a broad range of cytokines/chemokines and growth factors (84 in total) in the lungs of bleomycin-treated mice identified a novel and hitherto unknown set of cytokines/chemokines that appear to play a role in the pathogenesis of bleomycin-induced pneumonitis. These include: Ccl17; Ccl2; Ccl7; Cxcl10; Cxcl16; Il18; Il1rn; Lif; Spp1 and Gusb. While thrombin-induced and PAR1-mediated expression of Ccl2 and CXcl10 has been reported37,38, and PAR1 has been implicated in Ccl7 expression in the setting of acute neutrophilic lung inflammation32, the involvement of Ccl17, Cxcl16, Il18, Il1rn, Lif and Spp1 in bleomycin-induced lung injury has not been recognized. Identification of these cytokines/chemokines by this study provides additional opportunities to examine mechanisms of bleomycin/thrombin/PAR1-induced lung injury/inflammation, and identifies potential therapeutic targets to ameliorate pneumonitis in bleomycin-treated patients. Importantly, STC1 blunts the expression of most of these cytokines/chemokines in the lung after bleomycin treatment.

In summary, current data identify STC1 as a novel inhibitor of bleomycin-induced lung injury. Protection by STC1 is mediated through diminishing thrombin protein level and activity, suppression of superoxide production, and subsequently inhibition of ERK1/2 activation and the expression of pro-inflammatory and pro-fibrotic cytokines/chemokines. STC1 is a naturally occurring protein, which exists in the serum at low concentrations; thus, delivery of STC1 before anticipated bleomycin administration may constitute a prophylactic approach to ameliorate bleomycin-induced lung injury. These findings broaden the array of potential therapeutic targets for the treatment of lung diseases characterized by inflammation and fibrosis.

Additional Information

How to cite this article: Huang, L. et al. Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury. Sci. Rep. 5, 18117; doi: 10.1038/srep18117 (2015).

Acknowledgments

This work was supported by grants from the Veteran Administration [BX002006-01], National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health [R01 DK080306; T32 DK062706], and a generous gift from Dr. and Mrs. Harold Selzman. This project was also supported by the Pathology and Histology Core at Baylor College of Medicine with funding from the NIH (NCI P30-CA125123) and the expert assistance of Michael Ittmann, MD PhD.

Footnotes

Author Contributions L.H. and D.S.H. prepared figures and wrote the main manuscript text; L.Z., Q.L., H.J., J.S.-C.P. and Z.A.-L. performed the experiments. All authors reviewed the manuscript.

References

  1. Carver J. R. et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 25, 3991–4008 (2007). [DOI] [PubMed] [Google Scholar]
  2. Wilson M. S. & Wynn T. A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal. Immunol. 2, 103–121 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chambers R. C., Leoni P., Blanc-Brude O. P., Wembridge D. E. & Laurent G. J. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J. Biol. Chem. 275, 35584–35591 (2000). [DOI] [PubMed] [Google Scholar]
  4. Trejo J., Connolly A. J. & Coughlin S. R. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J. Biol. Chem. 271, 21536–21541 (1996). [DOI] [PubMed] [Google Scholar]
  5. Zhou S. Y. et al. Thrombin promotes human lung fibroblasts to proliferate via NADPH oxidase/reactive oxygen species/extracellular regulated kinase signaling pathway. Chin Med. J. (Engl.) 123, 2432–2439 (2010). [PubMed] [Google Scholar]
  6. De Niu P. et al. Development of a human stanniocalcin radioimmunoassay: serum and tissue hormone levels and pharmacokinetics in the rat. Mol. Cell Endocrinol. 162, 131–144 (2000). [DOI] [PubMed] [Google Scholar]
  7. Re R. N. & Cook J. L. The mitochondrial component of intracrine action. Am. J. Physiol Heart Circ. Physiol 299, H577–H583 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Wang Y. et al. Stanniocalcin-1 suppresses superoxide generation in macrophages through induction of mitochondrial UCP2. J. Leukoc. Biol. 86, 981–988 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chen C., Jamaluddin M. S., Yan S., Sheikh-Hamad D. & Yao Q. Human stanniocalcin-1 blocks TNF-alpha-induced monolayer permeability in human coronary artery endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 906–912 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chakraborty A. et al. Stanniocalcin-1 regulates endothelial gene expression and modulates transendothelial migration of leukocytes. Am. J. Physiol Renal Physiol 292, F895–F904 (2007). [DOI] [PubMed] [Google Scholar]
  11. Huang L. et al. Overexpression of stanniocalcin-1 inhibits reactive oxygen species and renal ischemia/reperfusion injury in mice. Kidney Int. 82, 867–877 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huang L. et al. Anti-inflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis. Am. J. Pathol. 174, 1368–1378 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Varghese R. et al. Overexpression of human stanniocalcin affects growth and reproduction in transgenic mice. Endocrinology 143, 868–876 (2002). [DOI] [PubMed] [Google Scholar]
  14. Hattori N. et al. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice. J. Clin. Invest 106, 1341–1350 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Li Y. et al. NMDA Receptor Antagonist Attenuates Bleomycin-Induced Acute Lung Injury. PLoS. ONE. 10, e0125873 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Green T. P., Johnson D. E., Marchessault R. P. & Gatto C. W. Transvascular flux and tissue accrual of Evans blue: effects of endotoxin and histamine. J. Lab Clin. Med. 111, 173–183 (1988). [PubMed] [Google Scholar]
  17. Krupiczojc M. A., Scotton C. J. & Chambers R. C. Coagulation signalling following tissue injury: focus on the role of factor Xa. Int. J. Biochem. Cell Biol. 40, 1228–1237 (2008). [DOI] [PubMed] [Google Scholar]
  18. Chambers R. C. Role of coagulation cascade proteases in lung repair and fibrosis. Eur. Respir. J. Suppl 44, 33s–35s (2003). [DOI] [PubMed] [Google Scholar]
  19. Tani K. et al. Thrombin enhances lung fibroblast proliferation in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 5, 34–40 (1991). [DOI] [PubMed] [Google Scholar]
  20. Huang L. et al. Thrombin promotes fibroblast proliferation during the early stages of experimental radiation pneumonitis. Radiat. Res. 156, 45–52 (2001). [DOI] [PubMed] [Google Scholar]
  21. Liu D. et al. Human stanniocalcin-1 suppresses angiotensin II-induced superoxide generation in cardiomyocytes through UCP3-mediated anti-oxidant pathway. PLoS. ONE. 7, e36994 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tanaka K. et al. Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am. J. Physiol Lung Cell Mol. Physiol 298, L348–L360 (2010). [DOI] [PubMed] [Google Scholar]
  23. Chambers R. C. et al. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem. J. 333 (Pt 1), 121–127 (1998). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Cunningham M. A. et al. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J. Exp. Med. 191, 455–462 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Song J. S., Kang C. M., Park C. K. & Yoon H. K. Thrombin induces epithelial-mesenchymal transition via PAR-1, PKC, and ERK1/2 pathways in A549 cells. Exp. Lung Res. 39, 336–348 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Deng X., Mercer P. F., Scotton C. J., Gilchrist A. & Chambers R. C. Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Galphaq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol. Biol. Cell 19, 2520–2533 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Chambers R. C. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br. J. Pharmacol. 153 Suppl 1, S367–S378 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sekiguchi F. et al. Biological activity of Helicobacter pylori components in mammalian cells: is it independent of proteinase-activated receptors? J. Physiol Pharmacol. 63, 571–576 (2012). [PubMed] [Google Scholar]
  29. Strande J. L. et al. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res. Cardiol. 102, 350–358 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kyriakis J. M. & Avruch J. Protein kinase cascades activated by stress and inflammatory cytokines 3. Bioessays 18, 567–577 (1996). [DOI] [PubMed] [Google Scholar]
  31. Troyanovsky B., Alvarez D. F., King J. A. & Schaphorst K. L. Thrombin enhances the barrier function of rat microvascular endothelium in a PAR-1-dependent manner. Am. J. Physiol Lung Cell Mol. Physiol 294, L266–L275 (2008). [DOI] [PubMed] [Google Scholar]
  32. Mercer P. F. et al. Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung inflammation. Am. J. Respir. Cell Mol. Biol. 50, 144–157 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Ono M. et al. Mesenchymal Stem Cells Correct Inappropriate Epithelial-Mesenchyme Relation in pulmonary fibrosis using Stanniocalcin-1. Mol. Ther. 50(1), 144–57 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Son Y. et al. Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways? J. Signal. Transduct. 2011, 792639 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Kishida K. T., Pao M., Holland S. M. & Klann E. NADPH oxidase is required for NMDA receptor-dependent activation of ERK in hippocampal area CA1. J. Neurochem. 94, 299–306 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Naito M. et al. Thrombin-activatable fibrinolysis inhibitor protects against acute lung injury by inhibiting the complement system. Am. J. Respir. Cell Mol. Biol. 49, 646–653 (2013). [DOI] [PubMed] [Google Scholar]
  37. Simmons S., Lee R. V., Moller T. & Weinstein J. R. Thrombin induces release of proinflammatory chemokines interleukin-8 and interferon-gamma-induced protein-10 from cultured human fetal astrocytes. Neuroreport 24, 36–40 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Ortiz-Stern A., Deng X., Smoktunowicz N., Mercer P. F. & Chambers R. C. PAR-1-dependent and PAR-independent pro-inflammatory signaling in human lung fibroblasts exposed to thrombin. J. Cell Physiol 227, 3575–3584 (2012). [DOI] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES